COMPANY Data
Companies by Sector
More than 6000 listed
My FAVORITES
Movers and SHAKERS
PsyBio Therapeutics Corp. (PSYBF)(PSYB:CA) - Initiating Coverage

Monday, August 09, 2021

PsyBio Therapeutics Corp. (PSYBF)(PSYB:CA)
Initiating Coverage

PsyBio Therapeutics is developing biosynthetic psychoactive compounds which offer a new paradigm of treatment to reverse the course of mental health issues. Psychoactive medications treat the illness by rewiring the brain through contemplation and a change of perception in combination with psychotherapy vs. Standard of care (SSRI’s, SNRI’s, MAOI’s, NDRI’s, etc…) which just chemically treat symptoms. Working in partnership with Miami University utilizing a proprietary platform technology to biologically synthesize psilocybin and other targeted next generation active compounds in Psilocybe Cubensis and other fungi and plants.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    PsyBio Therapeutics Is Developing Psychedelic Drugs For Therapeutic Use.  PsyBio is developing drugs to treat psychiatric disorders.  Its has a proprietary manufacturing process for making psilocybin, the active component in “magic mushrooms” as well as related psychedelic analogues. These compounds include norbaeocystin, baeocystine, aeruginocin, and DMT. PsyBio is developing these compounds as both monotherapies and combinations that could increase efficacy at lower doses.

    Biosynthetic Manufacturing Is A Strength. PsyBio has developed proprietary biosynthesis processes for producing psychedelic compounds.  The company can produce large quantities of these compounds at pharmaceutical specifications for potency, stability, and purity. This reduces the variability and cost compared with other methods. Its patent portfolio covers its biological manufacturing processes and ...




This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 



NEWS Channel
No News
RESEARCH Reports
No News
ChannelCast VIDEOS